ProTgen Information

Targeted Notch activators to reactivate the thymus and reconstitute the adaptive immune system for all patients. ProTgen is a biotechnology company developing a new class of transformative medicines designed to restore immune competence by unlocking the therapeutic potential of the Notch signaling pathway. Traditionally considered undruggable, ProTgen has overcome this barrier with a proprietary targeted Notch activator platform—a versatile technology capable of programming cell fate both in vivo and ex vivo. Our Science The adaptive immune system relies on the continuous generation of diverse T cells within the thymus. However, thymic function is highly sensitive to age, intensive medical treatments, and disease, leading to a profound decline in T cell diversity and overall immune competence. This immune compromise is a primary driver of poor clinical outcomes, including infection, malignancy, and chronic disease. ProTgen’s platform leverages the essential role of Notch signaling in regulating cell fate decisions. Our targeted Notch activators provide the precise signals required to direct hematopoietic stem cells toward a T-lineage fate, triggering the regeneration of thymic architecture and the reconstitution of a functional, polyclonal immune repertoire. Our Pipeline ProTgen is advancing a modular pipeline across multiple therapeutic modalities. Our lead program, ProT-096, is a personalized progenitor T-cell therapy for patients with refractory hematologic malignancies who have exhausted standard treatment options. ProT-096 is designed to restore long-term immune protection following intensive therapy. We are also leveraging our platform to develop in vivo biologics capable of directly programming cell fate within the body. Our vision extends to reversing age-related immune decline and providing foundational new treatments across oncology, regenerative medicine, and beyond. Our Team ProTgen is led by an experienced team of executives and world-leading ex